The COVID-19 pandemic has acted as a catalyst for the rapid implementation and development of wearable technology in the medical market. Wearable technologies, such as smartwatches and medical-grade wearables, have emerged as indispensable tools for remotely tracking glucose levels and managing diabetes. Following the wearable trend in medical, the recent update enables Apple Watch users to display glucose data directly from older Dexcom Continuous Glucose Monitoring (CGM) devices. The move is expected to cement Dexcom’s position in the wearable health technology space, says GlobalData, a leading data and analytics company.

According to GlobalData forecasts, the wearable tech industry was worth $99.5 billion in 2022 and will reach $290.6 billion by 2030, expanding at a compound annual growth rate (CAGR) of 14.3% between 2022 and 2030.

Kamilla Kan, Senior Data Scientist, Medical Devices team at GlobalData, comments: “The market is poised for growth, driven by increased sales of hearables and smartwatches. Moreover, the integration of artificial intelligence (AI) holds the potential to inaugurate a new era of interactive and intelligent wearable devices, thereby enhancing user experiences.”

Previously, Apple Watch users relied on iPhones to relay glucose data from Dexcom CGMs, resulting in potential delays and incomplete information due to Apple’s restrictions on third-party app refresh rates. However, with the latest update, Dexcom G7 revolutionizes the user experience by enabling direct Bluetooth connectivity between the CGM, smartphone, pump, and Apple Watch, allowing for real-time glucose monitoring directly on the wrist.

Kan concludes: “The pandemic has propelled the adoption of these technologies among healthcare professionals and patients alike, paving the way for a more connected and proactive approach to diabetes management both during and beyond the pandemic.

“With both Dexcom and Abbott securing FDA clearances for over-the-counter CGMs, the competition in the glucose monitoring market intensifies. However, Dexcom’s strategic investment in direct-to-watch integration demonstrates its commitment to innovation and user-centric design, positioning the company as a leader in the evolving landscape of wearable health technology.”